So Miyoshi

Background

About So Miyoshi

Dr. So Miyoshi is Head of Clinical Pharmacology and Bioanalytics at Pfizer R&D Japan. He has more than 20 years of experience in the application of quantitative clinical pharmacology and pharmacometrics for clinical development and new drug application work not only for Japan but also for the US, Europe, China, and Korea as a Global Clinical Pharmacology Lead and Pharmacometrician. Dr. Miyoshi received his PhD in Pharmaceutical Science from Kyushu University in 2008 after training at Pfizer UK and Uppsala University in pharmacometrics. Dr. Miyoshi has organized sessions and been invited as a speaker at many regional and intranational conferences including the Population Approach Group in Japan, the Japanese Society of Clinical Pharmacology and Therapeutics, and Drug Information Association (DIA). He is Community Lead of Clinical Pharmacology, which was established in December 2021, in DIA Japan. Dr. Miyoshi served as Leader of Clinical Pharmacology Task Force in the Japan Pharmaceutical Manufacturers Association (JPMA) in 2015-2020. During the period, he collaborated with regulatory authorities and academia, making efforts to establish Japanese pharmacometrics guidelines. He is Topic Leader of ICH Expert WG for Drug-Drug Interaction (M12) as JPMA representative. Dr. Miyoshi has been serving on the Board of Directors of the International Society of Pharmacometrics as an Asia representative since 2021 and will serve as Secretary for two years starting in 2024.